Export file:


  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text


  • Citation Only
  • Citation and Abstract

Genetically-engineered T cells to treat viral hepatitis-associated liver cancer: is it possible?

1 Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands
2 Department of Immunology, Nutricia Research, Utrecht, the Netherlands
3 Department of Immunology, Nutricia Research, Singapore

Adoptive T-cell immunotherapy is gaining credibility and popularity as a potential tool to cure cancer. Genetic engineering utilization of this therapeutic mode currently comes in the forms of chimeric antigen receptor- and T-cell receptor-engineered T cells. This short review focuses on opportunities to use engineered T cells to treat viral hepatitis-associated hepatocellular carcinoma.
  Article Metrics


1. June CH, Riddell SR, Schumacher TN (2015) Adoptive cellular therapy: a race to the finish line.Sci Transl Med 7: 280–287.

2. Harris DT, Kranz DM (2016) Adoptive T cell therapies: a comparison of t cell receptors and chimeric antigen receptors. Trends Pharmacol Sci 37: 220–230.    

3. Figueroa JA, Reidy A, Mirandola L, et al. (2015) Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol 34: 154–187.    

4. Ramos CA, Dotti G (2011) Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Th 11: 855–873.    

5. Porter DL, Levine BL, Kalos M, et al. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New Engl J Med 365: 725–733.    

6. Brentjens RJ, Davila ML, Riviere I, et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra38.

7. Grupp SA, Kalos M, Barrett D, et al. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New Engl J Med 368: 1509–1518.    

8. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385: 517–528.

9. Ramos CA, Heslop HE, Brenner MK (2016) CAR-T cell therapy for lymphoma. Annu Rev Med 67: 165–183.    

10. Vigneron N (2015) Human tumor antigens and cancer immunotherapy. Biomed Res Int 2015: 948501.

11. Linette GP, Stadtmauer EA, Maus MV, et al. (2013) Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122: 863–871.    

12. Morgan RA, Chinnasamy N, Abatedaga DD, et al. (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36: 133–151.    

13. Walker A, Johnson R (2016) Commercialization of cellular immunotherapies for cancer. Biochem Soc Trans 44: 329–332.    

14. Koh S, Shimasaki N, Suwanarusk R, et al. (2013) A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucl Acids 2: e114.    

15. Bertoletti A, Ferrari C (2016) Adaptive immunity in HBV infection. J Hepatol 64: S71–83.    

16. Jo J, Lohmann V, Bartenschlager R, et al. (2011) Experimental models to study the immunobiology of hepatitis C virus. J Gen Virol 92: 477–493.    

17. Pasetto A, Frelin L, Aleman S, et al. (2012) TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity. J Immunol 189: 4510–4519.    

18. Sautto GA, Wisskirchen K, Clementi N, et al. (2016) Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut 65: 512–523.    

19. Zhang Y, Liu YY, Moxley KM, et al. (2010) Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathog 6: e1001018.    

20. Balasiddaiah A, Davanian H, Aleman S, et al. (2017) Hepatitis C virus-specific T cell receptor mRNA-engineered human t cells: impact of antigen specificity on functional properties. J Virol 91: e00010–17.

21. Pawlotsky JM, Aghemo A, Back D (2017) EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66: 153–194.    

22. Krebs K (2013) T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 145: 456–465.    

23. Gehring AJ, Xue SA, Ho ZZ, et al. (2011) Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 55: 103–110.    

24. Banu N, Chia A, Zi ZH, et al. (2014) Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections. Sci Rep 4: 4166–4175.

25. Perz JF, Armstrong GL, Farrington LA, et al. (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529–538.    

26. Brechot C, Pourcel C, Louise A, et al. (1980) Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 286: 533–535.    

27. Qasim W, Brunetto M, Gehring A, et al. (2015) Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 62: 486–491.    

28. Koh S, Tan A, Li L, et al. (2016) Targeted therapy of hepatitis B virus-related hepatocellular carcinoma: present and future. Diseases 4: 10–16.    

29. Spear TT, Callender GG, Roszkowski JJ, et al. (2016) TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immun 65: 293–304.    

Copyright Info: © 2017, Juandy Jo, et al., licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Article outline

Show full outline
Copyright © AIMS Press All Rights Reserved